Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. (SHE:301126)

SHE:301126 Revenue

Tat Ka Wai Hong Pharmaceutical Industry Group had revenue of 1.34B CNY in the quarter ending September 30, 2026, a decrease of -6.05%. This brings the company's total for the last twelve months to 5.05B, down -6.11% year-over-year. In the year 2025, Tat Ka Wai Hong Pharmaceutical Industry Group had annual revenue of 5.14B, down -1.70%. That makes Tat Ka Wai Hong Pharmaceutical Industry Group the 8,967th largest company in the world by revenue and 1,411th in China.

• Revenue (ttm): 5.05B
• Revenue Growth: -6.11%
• P/S Ratio: 0.37
• Revenue / Employee: 946.16K
• Employees: 5,339
• Market Cap: 1.85B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Retail 2.94B 57.2%
• Pharmaceutical Distribution 1.96B 38.1%
• Drug production revenue 215.15M 4.2%
• Other Income 16.86M 0.3%
• Hospital income 10.66M 0.2%

Fiscal year ended Dec 31, 2025 See the full SHE:301126 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.14B	-89.18M	-1.70%
Dec 31, 2024	5.23B	1.33B	34.07%
Dec 31, 2023	3.90B	611.18M	18.56%
Jan 1, 2023	3.29B	700.15M	27.01%
Dec 31, 2021	2.59B	252.41M	10.79%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 29, 2026

Data Sources Report a data error